HPV

Eradicating Cervical Cancer One Step at a Time

Highlight

highlight

PathoScan hrHPV

logo-dark
logo-dark

Products & Solutions: Explore key applications in your field

Animal Diagnostics


Our Partners

East Ventures
Illumina
Biofarma
Kementerian Kesehatan
Innoquest
Laboratorium Cito
Diagnos Laboratory
Mandaya Hospital Group

Knowledge Hub

Paper & Publications

thumbnail

The efficiency of selective pooling strategy in a COVID-19 diagnostic laboratory

Introduction: Mass testing is essential in the surveillance strategy for fighting the COVID-19 pandemic. It allows early detection of suspected cases and subsequently early isolation to mitigate spread. However, the high cost and limited consumables and reagents hinder the mass testing strategy in developing countries such as Indonesia. The specimen pooling strategy is an option to perform mass screening with limited resources. This study aims to determine the positivity rate cut-off and to evaluate the efficiency of pooling strategy for the laboratory diagnosis of COVID-19.

Methodology: Between August 4th, 2020, and November 11th, 2020, a four-sample pooling strategy testing to detect SARS-CoV-2 was carried out at the Microbiology Diagnostic Laboratory of Diponegoro National Hospital, Semarang, Indonesia. Pools with positive results were subjected to individual specimen retesting. Spearman’s correlation and linear regression analysis were used to determine the best positivity rate cut-off to apply pooling strategy.

Results: A total of 15,216 individual specimens were pooled into 3,804 four-sample pools. Among these pools, 1,007 (26.47%) were positive. Five hundred and ten (50.64%) were 1/4 positive. A maximum positivity rate of 22% is needed to save at least 50% extraction and qRT-PCR reactions in a four-sample pooling strategy. CT values between individual specimens and pools showed a good interval agreement.

Conclusions: Pooling strategy could reduce personnel workload and reagent cost, and increase laboratory capacity by up to 50% when the positivity rate is less than 22%.

Career Highlight

Sales (Human Diagnostics)

BU Molecular Diagnostics Lead

Full-Time

Jakarta

Digital Products

Full Stack Developer

Full-Time

Jakarta

Technical Operations

Manufacturing/Lab Biotechnologist

Full-Time

Jakarta

logo-dark
logo-dark

The most established precision molecular diagnostics company in Indonesia

Find Us

Mon - Fri: 9 a.m. - 6 p.m.

i3L Campus @ Lvl. 3
Jl. Pulomas Barat No.Kav.88, RT.4/RW.9, Kayu Putih, Pulo Gadung,
Jakarta Timur 13210

Contact Us

hello@nusantics.com

+62 (21) 509 194 30

Copyright © 2024. All rights reserved.Privacy Policy

logo-dark
logo-dark

Copyright © 2024. All rights reserved.

Privacy Policy